Bronchodilator responsiveness in children with asthma is not influenced by spacer device selection

Nina D'Vaz, Toluwalose Okitika, Claire Shackleton, Sunalene Devadason, Graham Hall

Research output: Contribution to journalArticle

Abstract

Introduction: Spacer devices optimize delivery of aerosol therapies and maximize therapeutic efficacy. We assessed the impact of spacer device on the prevalence and magnitude of bronchodilator response (BDR) in children with asthma.

Methods: Children with physician confirmed asthma and parentally reported symptoms in the last 12 months were recruited for this study. Each participant completed two separate visits (5-10 days apart) with spirometry performed at baseline and following cumulative doses of salbutamol (200, 400, 800, and 1200μg) delivered by either a small volume disposable spacer or a large volume multi-use spacer. Spacer type was alternated for each participant during each visit. The primary outcome was the effect of spacer type on bronchodilator responsiveness. The secondary outcome was to assess the relationships between spacer device, salbutamol dose and the proportion of children with a clinically relevant BDR.

Results: Thirty-two children (mean age 11.8 years) completed both visits. Change in lung function following bronchodilators was increased using the large volume spacer, for relative but not absolute increase in FEV1 [mean difference (95% confidence intervals): 1.28% (0.02, 2.54; P=0.047) and 0.013L (−0.01, 0.04; P=0.288)], respectively. There was no observed difference in FVC by spacer type. Overall, 59% (n=19) of children exhibited a clinically relevant BDR at 400μg of salbutamol for any spacer and was independent of spacer type.

Conclusion: Spacer device was not associated with clinically important differences in lung function following bronchodilator inhalation in children with asthma. At a recommended dose of 400μg, some children with asthma may have their bronchodilator responsiveness misclassified.
Original languageEnglish
Pages (from-to)531-536
JournalPediatric Pulmonology
Volume54
Issue number5
Early online date4 Feb 2019
DOIs
Publication statusPublished - May 2019

Fingerprint

Bronchodilator Agents
Asthma
Equipment and Supplies
Albuterol
Lung
Spirometry
Aerosols
Inhalation
Confidence Intervals
Physicians
Therapeutics

Cite this

D'Vaz, Nina ; Okitika, Toluwalose ; Shackleton, Claire ; Devadason, Sunalene ; Hall, Graham. / Bronchodilator responsiveness in children with asthma is not influenced by spacer device selection. In: Pediatric Pulmonology. 2019 ; Vol. 54, No. 5. pp. 531-536.
@article{f53a3732cbe14bf8afec6c418b2ed1f1,
title = "Bronchodilator responsiveness in children with asthma is not influenced by spacer device selection",
abstract = "Introduction: Spacer devices optimize delivery of aerosol therapies and maximize therapeutic efficacy. We assessed the impact of spacer device on the prevalence and magnitude of bronchodilator response (BDR) in children with asthma.Methods: Children with physician confirmed asthma and parentally reported symptoms in the last 12 months were recruited for this study. Each participant completed two separate visits (5-10 days apart) with spirometry performed at baseline and following cumulative doses of salbutamol (200, 400, 800, and 1200μg) delivered by either a small volume disposable spacer or a large volume multi-use spacer. Spacer type was alternated for each participant during each visit. The primary outcome was the effect of spacer type on bronchodilator responsiveness. The secondary outcome was to assess the relationships between spacer device, salbutamol dose and the proportion of children with a clinically relevant BDR.Results: Thirty-two children (mean age 11.8 years) completed both visits. Change in lung function following bronchodilators was increased using the large volume spacer, for relative but not absolute increase in FEV1 [mean difference (95{\%} confidence intervals): 1.28{\%} (0.02, 2.54; P=0.047) and 0.013L (−0.01, 0.04; P=0.288)], respectively. There was no observed difference in FVC by spacer type. Overall, 59{\%} (n=19) of children exhibited a clinically relevant BDR at 400μg of salbutamol for any spacer and was independent of spacer type.Conclusion: Spacer device was not associated with clinically important differences in lung function following bronchodilator inhalation in children with asthma. At a recommended dose of 400μg, some children with asthma may have their bronchodilator responsiveness misclassified.",
author = "Nina D'Vaz and Toluwalose Okitika and Claire Shackleton and Sunalene Devadason and Graham Hall",
year = "2019",
month = "5",
doi = "10.1002/ppul.24263",
language = "English",
volume = "54",
pages = "531--536",
journal = "Pediatric Pulmonology",
issn = "1099-0496",
publisher = "John Wiley & Sons",
number = "5",

}

Bronchodilator responsiveness in children with asthma is not influenced by spacer device selection. / D'Vaz, Nina; Okitika, Toluwalose; Shackleton, Claire; Devadason, Sunalene; Hall, Graham.

In: Pediatric Pulmonology, Vol. 54, No. 5, 05.2019, p. 531-536.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bronchodilator responsiveness in children with asthma is not influenced by spacer device selection

AU - D'Vaz, Nina

AU - Okitika, Toluwalose

AU - Shackleton, Claire

AU - Devadason, Sunalene

AU - Hall, Graham

PY - 2019/5

Y1 - 2019/5

N2 - Introduction: Spacer devices optimize delivery of aerosol therapies and maximize therapeutic efficacy. We assessed the impact of spacer device on the prevalence and magnitude of bronchodilator response (BDR) in children with asthma.Methods: Children with physician confirmed asthma and parentally reported symptoms in the last 12 months were recruited for this study. Each participant completed two separate visits (5-10 days apart) with spirometry performed at baseline and following cumulative doses of salbutamol (200, 400, 800, and 1200μg) delivered by either a small volume disposable spacer or a large volume multi-use spacer. Spacer type was alternated for each participant during each visit. The primary outcome was the effect of spacer type on bronchodilator responsiveness. The secondary outcome was to assess the relationships between spacer device, salbutamol dose and the proportion of children with a clinically relevant BDR.Results: Thirty-two children (mean age 11.8 years) completed both visits. Change in lung function following bronchodilators was increased using the large volume spacer, for relative but not absolute increase in FEV1 [mean difference (95% confidence intervals): 1.28% (0.02, 2.54; P=0.047) and 0.013L (−0.01, 0.04; P=0.288)], respectively. There was no observed difference in FVC by spacer type. Overall, 59% (n=19) of children exhibited a clinically relevant BDR at 400μg of salbutamol for any spacer and was independent of spacer type.Conclusion: Spacer device was not associated with clinically important differences in lung function following bronchodilator inhalation in children with asthma. At a recommended dose of 400μg, some children with asthma may have their bronchodilator responsiveness misclassified.

AB - Introduction: Spacer devices optimize delivery of aerosol therapies and maximize therapeutic efficacy. We assessed the impact of spacer device on the prevalence and magnitude of bronchodilator response (BDR) in children with asthma.Methods: Children with physician confirmed asthma and parentally reported symptoms in the last 12 months were recruited for this study. Each participant completed two separate visits (5-10 days apart) with spirometry performed at baseline and following cumulative doses of salbutamol (200, 400, 800, and 1200μg) delivered by either a small volume disposable spacer or a large volume multi-use spacer. Spacer type was alternated for each participant during each visit. The primary outcome was the effect of spacer type on bronchodilator responsiveness. The secondary outcome was to assess the relationships between spacer device, salbutamol dose and the proportion of children with a clinically relevant BDR.Results: Thirty-two children (mean age 11.8 years) completed both visits. Change in lung function following bronchodilators was increased using the large volume spacer, for relative but not absolute increase in FEV1 [mean difference (95% confidence intervals): 1.28% (0.02, 2.54; P=0.047) and 0.013L (−0.01, 0.04; P=0.288)], respectively. There was no observed difference in FVC by spacer type. Overall, 59% (n=19) of children exhibited a clinically relevant BDR at 400μg of salbutamol for any spacer and was independent of spacer type.Conclusion: Spacer device was not associated with clinically important differences in lung function following bronchodilator inhalation in children with asthma. At a recommended dose of 400μg, some children with asthma may have their bronchodilator responsiveness misclassified.

U2 - 10.1002/ppul.24263

DO - 10.1002/ppul.24263

M3 - Article

VL - 54

SP - 531

EP - 536

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 1099-0496

IS - 5

ER -